Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bucillamine in Patients With Mild-Moderate COVID-19
NCT04504734Phase 3Terminated
- Sponsor
- Revive Therapeutics
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of bucillamine in coronavirus disease 2019 (COVID-19), sponsored by Revive Therapeutics. Started Nov 2020; status: terminated.
02
Drugs
bucillamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04504734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504734.